Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27,196,692
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
8,180,851
-
Shares change
-
+8,180,349
-
Total reported value, excl. options
-
$52,679,353
-
Value change
-
+$52,676,156
-
Put/Call ratio
-
8.83%
-
Number of buys
-
37
-
Price
-
$6.44
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q3 2022
40 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q3 2022.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8,180,851 shares
of 27,196,692 outstanding shares and own 30.08% of the company stock.
Largest 10 shareholders include Artal Group S.A. (1,463,829 shares), Bain Capital Life Sciences Investors, LLC (1,082,404 shares), Flagship Pioneering Inc. (993,848 shares), Avidity Partners Management LP (900,000 shares), Ally Bridge Group (NY) LLC (868,403 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (721,914 shares), VANGUARD GROUP INC (487,533 shares), CVI Holdings, LLC (425,500 shares), DAFNA Capital Management LLC (265,878 shares), and FMR LLC (252,029 shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.